Value chain — stage 03
Regulatory affairs
Submission authoring, labelling, RIM, health-authority responses and regulatory intelligence — plus what the FDA and EMA now expect you to prove about the model itself.
- Submission authoring & publishing
- Labelling & IDMP
- Regulatory information management
- Health-authority correspondence
- Regulatory intelligence
Start here
The guide
The long, definitive pieces on regulatory. Everything else on this page goes deeper on one part of them.
In depth
6 articles
Specific problems, specific answers, each written against a named source and dated.
- 01Named Data Ownership Beats Any AgentOne organisation in fifty-nine is ready; the variable predicting regulatory operations performance is accountability for data, not artificial intelligence. today
- 02Costing a Health Authority Query Response Before You Automate ItQuery volume, hours per response, Module 3 hotspots: building a credible automation business case from measured baselines, not vendor claims.
- 03Your FDA Reviewer Switched ModelsElsa moved from Claude to Gemini mid-review; what a regulator-side model swap does to consistency, and to your submission strategy.
- 04What EMA Permits When AI Drafts Your Product InformationReflection paper section 2.3.5 read closely, plus the structured product information roadmap that makes labelling automation genuinely workable at scale.
- 05eCTD 4.0 in Japan, Europe and America — and Why Publishing Should Stay DeterministicAuthority timelines compared, gateway validation failure rates explained, and the architectural line separating rules engines from generative authoring further upstream.
- 06Ninety-Seven Percent Faster, Seventy Percent CompleteInside the Takeda IND benchmark: where drafting time went, which quality dimensions collapsed, and what human review must still catch.